Venus Remedies Ltd

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, faced intense selling pressure on 18 Mar 2026, hitting its lower circuit limit and registering a maximum daily loss of 5%. The stock’s sharp decline reflects a sudden shift in investor sentiment, marked by panic selling and a significant volume of unfilled supply.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has surged to a new 52-week and all-time high of Rs.950, marking a significant milestone in its market performance. This achievement reflects strong momentum driven by robust financial results and sustained gains over recent sessions.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs.950 on 17 Mar 2026, underscoring its robust performance and sustained growth trajectory. The stock’s recent surge reflects strong fundamentals and consistent positive results over multiple quarters.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 13 Mar 2026, hitting its lower circuit limit with a 5.0% drop to ₹881.15. The stock’s fall came after a seven-day rally, reflecting intense selling pressure and panic among investors despite the company’s recent strong technical positioning and a Mojo Grade upgrade to Buy.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone today by hitting a new 52-week and all-time high of Rs.946.1. This achievement marks a continuation of the stock’s strong upward momentum over the past year, reflecting robust financial performance and sustained investor confidence.

Venus Remedies Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs.946.1 on 13 Mar 2026, underscoring its robust performance and sustained growth trajectory in a competitive industry landscape.

Venus Remedies Ltd has been upgraded from a Hold to a Buy rating, reflecting significant improvements across technical indicators, valuation metrics, financial trends, and overall quality. The pharmaceutical and biotechnology company’s recent performance and market behaviour have prompted this positive reassessment, signalling renewed investor confidence and potential for sustained growth.

Venus Remedies Ltd has demonstrated a significant shift in price momentum, reflected in a strong 7.46% gain on 13 Mar 2026, alongside an upgrade in its MarketsMOJO Mojo Grade from Hold to Buy. This micro-cap pharmaceutical stock is exhibiting bullish technical signals across multiple timeframes, signalling renewed investor confidence and potential for sustained upward movement.

Venus Remedies Ltd has surged to a fresh 52-week and all-time high of Rs.912, marking a significant milestone in its market performance. This rally underscores the stock’s strong momentum amid a challenging broader market environment.

Venus Remedies Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 11 Mar 2026. This adjustment reflects a nuanced assessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. Despite robust quarterly earnings and strong institutional interest, concerns over valuation premiums and long-term sales growth have tempered enthusiasm among analysts.

Venus Remedies Ltd surged to a new 52-week and all-time high on 11 Mar 2026, hitting the upper circuit limit with a remarkable 9.97% gain. The pharmaceutical and biotechnology company demonstrated strong buying pressure amid rising investor participation, outperforming its sector and broader market indices in a notable display of bullish sentiment.

Venus Remedies Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 01 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 March 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.

Venus Remedies Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 01 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 09 March 2026, providing investors with the latest insights into its performance and outlook.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 25 Feb 2026, hitting its lower circuit limit amid intense selling pressure. The stock closed at ₹688.90, down 2.96% on the day, marking its fifth consecutive day of losses and reflecting mounting investor concerns and panic selling.

Venus Remedies Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 01 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Venus Remedies Ltd (Stock ID: 568580) surged to its upper circuit limit on 18 Feb 2026, closing at ₹786.60, marking a maximum daily gain of 5.0%. The micro-cap pharmaceutical and biotechnology company witnessed robust buying interest, outperforming its sector and broader market indices despite subdued investor participation.

Venus Remedies Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 01 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 13 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.